J
Jean-Paul Bahary
Researcher at Université de Montréal
Publications - 142
Citations - 4943
Jean-Paul Bahary is an academic researcher from Université de Montréal. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 25, co-authored 118 publications receiving 4291 citations. Previous affiliations of Jean-Paul Bahary include McGill University & Martin University.
Papers
More filters
Journal ArticleDOI
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
David W. Andrews,Charles B. Scott,Paul W. Sperduto,Adam E. Flanders,Laurie E. Gaspar,Michael C. Schell,Maria Werner-Wasik,W. Demas,J. Ryu,Jean-Paul Bahary,Luis Souhami,Marvin Rotman,Minesh P. Mehta,Walter J. Curran +13 more
TL;DR: WBRT and stereotactic radiosurgery should, therefore, be standard treatment for patients with a single unresectable brain metastasis and considered for Patients with two or three brain metastases.
Journal ArticleDOI
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles Catton,Himu Lukka,Chu-Shu Gu,Jarad Martin,Stéphane Supiot,Peter Chung,Glenn Bauman,Jean-Paul Bahary,Shahida Ahmed,Patrick Cheung,Keen Hun Tai,Jackson S.Y. Wu,Matthew Parliament,Theodoros Tsakiridis,Tom Corbett,Colin Tang,Ian S. Dayes,Padraig Warde,Tim Craig,Jim A. Julian,Mark Levine +20 more
TL;DR: The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity, and should be considered for intermediate-risk prostate cancer.
Journal ArticleDOI
Preliminary Toxicity Analysis of 3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy on the High-Dose Arm of the Radiation Therapy Oncology Group 0126 Prostate Cancer Trial
Jeff M. Michalski,Y. Yan,Deborah Watkins-Bruner,Walter Bosch,Kathryn Winter,James M. Galvin,Jean-Paul Bahary,Gerard Morton,Matthew Parliament,Howard M. Sandler +9 more
TL;DR: There is a trend for a clinically meaningful reduction in late G2+ GI toxicity with IMRT, and the occurrence of acute GI toxicity and large (>15%) volumes of rectum >70 Gy are associated with late rectal toxicity.
Journal ArticleDOI
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Jeff M. Michalski,Jennifer Moughan,James A. Purdy,Walter R. Bosch,Deborah Watkins Bruner,Jean-Paul Bahary,Harold Lau,Marie Duclos,Matthew Parliament,Gerard Morton,Daniel A. Hamstra,Daniel A. Hamstra,Michael I. Seider,Michael Lock,Malti Patel,Eric Vigneault,Kathryn Winter,Howard M. Sandler +17 more
TL;DR: Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS and high doses caused more late toxic effects but lower rates of salvage therapy.
Journal ArticleDOI
Single-Arm, Open-Label Phase II Study of Intravenously Administered Tirapazamine and Radiation Therapy for Glioblastoma Multiforme
J. Del Rowe,Charles B. Scott,Maria Werner-Wasik,Jean-Paul Bahary,Walter J. Curran,Raul C. Urtasun,Barbara Fisher +6 more
TL;DR: Survival in the population treated with radiation and tirapazamine was equivalent to the control population, and patients in RPA class III treated with Radiation Therapy Oncology Group (RTOG) patients with glioblastoma multiforme patients had a longer survival when compared with the historical controls.